|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/23 Sarepta Therapeutics, Inc. 10-K 12/31/22 119:23M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 6.67M
2: EX-10 Ex-10.70 HTML 50K
3: EX-10 Ex-10.72 HTML 39K
4: EX-10 Ex-10.73 HTML 260K
5: EX-21 Ex-21.1 HTML 33K
6: EX-23 Ex-23.1 HTML 32K
7: EX-31 Ex-31.1 HTML 36K
8: EX-31 Ex-31.2 HTML 36K
9: EX-32 Ex-32.1 HTML 35K
10: EX-32 Ex-32.2 HTML 35K
16: R1 Document and Entity Information HTML 103K
17: R2 Consolidated Balance Sheets HTML 138K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
19: R4 Consolidated Statements of Operations and HTML 137K
Comprehensive Loss
20: R5 Consolidated Statements of Stockholders' Equity HTML 100K
21: R6 Consolidated Statements of Cash Flows HTML 171K
22: R7 Organization and Nature of Business HTML 40K
23: R8 Summary of Significant Accounting Policies and HTML 134K
Recent Accounting Pronouncements
24: R9 License and Collaboration Agreements HTML 125K
25: R10 Gain From Sale of Priority Review Voucher HTML 37K
26: R11 Fair Value Measurements HTML 258K
27: R12 Cash, Cash Equivalents and Marketable Securities HTML 198K
28: R13 Product Revenues, Net, Accounts Receivable and HTML 146K
Reserves for Product Revenues
29: R14 Inventory HTML 80K
30: R15 Other Assets HTML 118K
31: R16 Property and Equipment, Net HTML 91K
32: R17 Intangible Assets, Net HTML 94K
33: R18 Accrued Expenses HTML 87K
34: R19 Indebtedness HTML 175K
35: R20 Equity HTML 44K
36: R21 Stock-Based Compensation HTML 288K
37: R22 401 (K) Plan HTML 41K
38: R23 Other (Loss) Income, Net HTML 102K
39: R24 Income Taxes HTML 335K
40: R25 Leases HTML 128K
41: R26 Net Loss Per Share HTML 80K
42: R27 Commitments and Contingencies HTML 91K
43: R28 Summary of Significant Accounting Policies and HTML 189K
Recent Accounting Pronouncements (Policies)
44: R29 Summary of Significant Accounting Policies and HTML 50K
Recent Accounting Pronouncements (Tables)
45: R30 Fair Value Measurements (Tables) HTML 254K
46: R31 Cash, Cash Equivalents and Marketable Securities HTML 197K
(Tables)
47: R32 Product Revenues, Net, Accounts Receivable and HTML 131K
Reserves for Product Revenues (Tables)
48: R33 Inventory (Tables) HTML 82K
49: R34 Other Assets (Tables) HTML 119K
50: R35 Property and Equipment, Net (Tables) HTML 88K
51: R36 Intangible Assets, Net (Tables) HTML 87K
52: R37 Accrued Expenses (Tables) HTML 86K
53: R38 Indebtedness (Tables) HTML 114K
54: R39 Stock-Based Compensation (Tables) HTML 272K
55: R40 Other (Loss) Income, Net (Tables) HTML 101K
56: R41 Income Taxes (Tables) HTML 322K
57: R42 Leases (Tables) HTML 112K
58: R43 Net Loss Per Share (Tables) HTML 78K
59: R44 Commitments and Contingencies (Tables) HTML 54K
60: R45 Organization and Nature of Business - Additional HTML 44K
Information (Detail)
61: R46 Summary of Significant Accounting Policies and HTML 90K
Recent Accounting Pronouncements - Additional
Information (Detail)
62: R47 Summary of Estimated Useful Lives of Plant and HTML 57K
Equipment (Detail)
63: R48 License and Collaboration Agreements - Additional HTML 317K
Information (Detail)
64: R49 Gain from Sale of Priority Review Voucher - HTML 35K
Additional Information (Detail)
65: R50 Assets and Liabilities Measured and Carried at HTML 71K
Fair Value (Detail)
66: R51 Summary of Fair Value of Level 3 Financial Assets HTML 41K
(Details)
67: R52 Summary of Fair Value of Level 3 Financial HTML 42K
Liabilities (Detail)
68: R53 Fair Value Measurements - Additional Information HTML 36K
(Detail)
69: R54 Summary of Company Financial Assets with HTML 43K
Maturities of Less Than 90 Days Included in Cash
Equivalents (Detail)
70: R55 Cash, Cash Equivalents and Marketable Securities - HTML 36K
Additional Information (Detail)
71: R56 Summary of Company Cash, Cash Equivalents and HTML 81K
Investments (Detail)
72: R57 Product Revenues, Net, Accounts Receivable and HTML 70K
Reserves for Product Revenues (Additional
Information) (Details)
73: R58 Summary of product revenues, net by product HTML 37K
(Details)
74: R59 Summary of Components of Accounts Receivable HTML 36K
(Detail)
75: R60 ACCOUNTS RECEIVABLE AND RESERVES FOR PRODUCT HTML 52K
REVENUES - Summary of Change in Reserves for
Discounts and Allowances (Detail)
76: R61 ACCOUNTS RECEIVABLE AND RESERVES FOR PRODUCT HTML 38K
REVENUES - Summary of Total Reserves Included in
Consolidated Balance Sheets (Detail)
77: R62 INVENTORY - Summary of Components of Inventory HTML 41K
(Detail)
78: R63 INVENTORY - Summarizes The Balance Sheet HTML 38K
Classification (Details)
79: R64 OTHER ASSETS - Summary of Other Current Assets HTML 55K
(Detail)
80: R65 OTHER ASSETS - Summary of Other Non-current Assets HTML 46K
(Detail)
81: R66 Summarizes Components of Property and Equipment, HTML 60K
Net (Detail)
82: R67 Property and Equipment, Net - Additional HTML 34K
Information (Detail)
83: R68 Intangible Assets, Net - Summary of Components of HTML 46K
Intangible Assets (Detail)
84: R69 Intangible Assets, Net - Additional Information HTML 59K
(Detail)
85: R70 Intangible Assets, Net - Summary of Estimated HTML 47K
Future Amortization for Intangible Assets (Detail)
86: R71 ACCRUED EXPENSES - Summary of Accrued Expenses HTML 57K
(Detail)
87: R72 Indebtedness - Additional Information (Detail) HTML 197K
88: R73 Indebtedness - Summary of Debt Facilities (Detail) HTML 58K
89: R74 Indebtedness - Summarizes Total Gross Payments Due HTML 52K
under Company's Debt Arrangements (Detail)
90: R75 Equity - Additional Information (Detail) HTML 49K
91: R76 Stock Based Compensation - Additional Information HTML 139K
(Detail)
92: R77 Assumptions for Measuring Fair Values of Stocks HTML 54K
(Detail)
93: R78 Assumptions for Measuring Fair Values of Stocks HTML 34K
(Parenthetical) (Detail)
94: R79 Summary of Stock Option Activity (Detail) HTML 83K
95: R80 Summary of Company's Stock Options Vested and HTML 36K
Exercised (Detail)
96: R81 Summary of Restricted Stock Unit Activity (Detail) HTML 58K
97: R82 Summary of Employee Stock Purchase Plan Activity HTML 38K
and Expense (Detail)
98: R83 Summary of Stock-Based Compensation Expense by HTML 39K
Function Included within Consolidated Statements
of Operations and Comprehensive Loss (Detail)
99: R84 Summary of Stock-Based Compensation Expense by HTML 42K
Grant Type Included within Consolidated Statements
of Operations and Comprehensive Loss (Detail)
100: R85 401 (K) PLAN - Additional Information (Detail) HTML 43K
101: R86 Summary of Other (Loss) Income, Net (Detail) HTML 56K
102: R87 Summary of Loss before Provision (Benefit) for HTML 42K
Income Taxes by Jurisdiction (Detail)
103: R88 Summary of Provision (Benefit) for Income Taxes HTML 61K
(Detail)
104: R89 Reconciliation Between Effective Tax Rate and HTML 54K
Statutory Income Tax Rate (Detail)
105: R90 Income Taxes - Additional Information (Detail) HTML 69K
106: R91 Analysis of Deferred Tax Assets and Liabilities HTML 65K
(Detail)
107: R92 Reconciliation of Beginning and Ending Amount of HTML 41K
Unrecognized Tax Benefits (Detail)
108: R93 Leases - Additional Information (Detail) HTML 64K
109: R94 Summary of Lease Costs Recognized Under Topic 842 HTML 50K
and Other Information Pertaining to Operating
Leases (Detail)
110: R95 Summary of Maturities of Lease Liabilities and HTML 60K
Reconciliation of Lease Liabilities Recognized
Under Topic 842 (Detail)
111: R96 Net Loss Per Share - Basic and Diluted Net Loss HTML 72K
Per Share (Detail)
112: R97 Net Loss Per Share - Basic and Diluted Net Loss HTML 41K
Per Share (Parenthetical) (Detail)
113: R98 Commitments and Contingencies - Additional HTML 92K
Information (Detail)
114: R99 Summary of Non-Cancelable Contractual Obligations HTML 45K
Arising From Long-term Contractual Arrangements
(Detail)
117: XML IDEA XML File -- Filing Summary XML 221K
115: XML XBRL Instance -- srpt-20221231_htm XML 5.15M
116: EXCEL IDEA Workbook of Financial Reports XLSX 265K
15: EX-101.CAL XBRL Calculations -- srpt-20221231_cal XML 323K
13: EX-101.DEF XBRL Definitions -- srpt-20221231_def XML 1.02M
14: EX-101.LAB XBRL Labels -- srpt-20221231_lab XML 2.28M
12: EX-101.PRE XBRL Presentations -- srpt-20221231_pre XML 1.71M
11: EX-101.SCH XBRL Schema -- srpt-20221231 XSD 343K
118: JSON XBRL Instance as JSON Data -- MetaLinks 690± 1.12M
119: ZIP XBRL Zipped Folder -- 0000950170-23-005062-xbrl Zip 1.23M
| EX-21 |
EXHIBIT 21.1
Sarepta Therapeutics, Inc.
Subsidiaries of the Registrant
Name |
Jurisdiction of Incorporation |
Sarepta Securities Corp. |
Massachusetts, USA |
ST International Holdings Two, Inc. |
Delaware, USA |
Sarepta Therapeutics Three, LLC |
Delaware, USA |
|
|
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 2/28/24 Sarepta Therapeutics, Inc. 10-K 12/31/23 119:18M Donnelley … Solutions/FA |